Evidence map›Paper›PMID 26883400›Full record

ArticleAIDS care2016

Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.

Luis Sagaon-Teyssier, Marie Suzan-Monti, Baptiste Demoulin, Catherine Capitant, Nicolas Lorente, Marie Préau, Marion Mora, Daniela Rojas Castro, Christian Chidiac, Julie Chas and 4 more

Open access · hybridAbstract read
In one paragraph

Article in AIDS care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 2 countries.

Luis Sagaon-Teyssiera INSERM, UMR912 (SESSTIM) , Marseille , France.
Marie Suzan-Montia INSERM, UMR912 (SESSTIM) , Marseille , France.
Baptiste Demoulina INSERM, UMR912 (SESSTIM) , Marseille , France.
Catherine Capitantd Inserm SC10 , Villejuif , France.
Nicolas Lorentea INSERM, UMR912 (SESSTIM) , Marseille , France.
Marie Préaua INSERM, UMR912 (SESSTIM) , Marseille , France.
Marion Moraa INSERM, UMR912 (SESSTIM) , Marseille , France.
Daniela Rojas Castrof GRePS Lyon 2 Université , Bron , France.
Christian Chidiach Department of Infectious Diseases , Hôpital de la Croix Rousse, INSERM U1052 , Lyon , France.
Julie Chasi Department of Infectious Diseases , Hôpital Tenon , Paris , France.
Laurence Meyerd Inserm SC10 , Villejuif , France.
Jean-Michel Molinaj Department of Infectious Disease , Assistance Publique Hôpitaux de Paris, University of Paris Diderot Paris 7, INSERM U941 , Paris , France.
Bruno Spirea INSERM, UMR912 (SESSTIM) , Marseille , France.
ANRS IPERGAY Study Group
Inserm · FRAgència de Salut Pública de Catalunya · ESAix-Marseille Université · FRARPE PACA · FRCentre de Recherche en Cancérologie de Lyon · FRDélégation Paris 7 · FREconomic & Social Sciences, Health Systems & Medical Informatics · FRGroupe de Recherche en Psychologie Sociale · FRHôpital Tenon · FRInstitut de Recherche pour le Développement · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The double-blind phase of the randomized ANRS IPERGAY trial, evaluating sexual activity-based oral HIV pre-exposure prophylaxis (PrEP), was conducted among high-risk men who have sex with men (MSM). Results showed an 86% (95% CI: 40-98) relative reduction in HIV incidence among participants with tenofovir disoproxil fumarate-emtricitabine vs. placebo. The present pooled analysis aimed to analyze (i) participants' adherence to the prescribed treatment and/or condom use during sexual intercourse and (ii) sexual behavior during the double-blind phase of the study. Four hundred MSM were enrolled in the trial. Every 2 months they completed online questionnaires collecting sexual behavior and PrEP adherence data regarding their most recent sexual intercourse. A total of 2232 questionnaires (M0-M24) were analyzed. Changes over time were evaluated using a mixed model accounting for multiple measures. Irrespective of sexual partner and practice type, on average, 42.6% (min: 32.1-max: 45.8%) reported PrEP use only during their most recent episode of sexual intercourse; 29% (22.9-35.6%) reported both PrEP and condom use; 11.7% (7.2-18.9%) reported condom-use only, and 16.7% (10.8-29.6%) reported no PrEP or condom use with no significant change during the study. Scheduled (i.e., correct) PrEP use was reported on average by 59.0% (47.2-68.5%) of those reporting PrEP use during their most recent sexual intercourse. Overall, 70.3% (65.3-79.4%) and 69.3% (58.3-75.4%) of participants reported, respectively, condomless anal and condomless receptive anal intercourse during their most recent sexual encounter without significant change during follow-up. Overall, on average 83.3% (min: 70.4-max: 89.2%) of participants protected themselves by PrEP intake or condom use or both during the trial, and no increase in at-risk sexual practices was observed. None of these indicators showed significant trend during the follow-up, although we found a tendency toward decrease (p = .19) of the median number of sexual partners strengthening the absence of behavioral disinhibition. On-demand PrEP within a comprehensive HIV prevention package could improve prevention in MSM.

Indexed as

Drug MonitoringPre-Exposure ProphylaxisRisk-TakingAdolescentAnti-HIV AgentsCanadaCondomsDeoxycytidineDouble-Blind MethodEmtricitabineFollow-Up StudiesFranceHIV InfectionsHomosexuality, MaleHumansMaleAnti-HIV AgentsDeoxycytidineEmtricitabineOrganophosphonatesTenofoviradherenceMSMOn-demand HIV pre-exposure prophylaxissexual behavior

Identifiers

PMID26883400
PMCPMC4828609
OpenAlexW2281762096

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.